Keppra 1000 mg

国家: 约旦

语言: 英文

来源: JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

有效成分:

Levetiracetam 1000 mg

可用日期:

مستودع أدوية سليمان طنوس وأولاده - Suleiman Tannous & Sons Co. Ltd

ATC代码:

N03AX14

INN（国际名称）:

Levetiracetam 1000 mg

剂量:

1000 mg

每包单位数:

100

厂商:

يوسي بي فارما (بلجيكا)

產品總結:

97.6 :سعر الجمهور + الضريبة

资料单张

HARMONY
_Packaging artwork and technical drawings _
_Approval Information_
Page 1 of 3
PROJECT:
CO-0042959
DOCUMENT:
PPC-0027412.pdf
DOCUMENT DESCRIPTION:
VERSION:
3
VERSION ID:
00002_0001104088
DOWNLOADED:
Sep 8, 2021 at 10:04 AM GMT+04:00
BY:
Lakkis, Fadilla (FML41544)
APPROVAL STATE:
DRAFT
PATIENT LEAFLET
250 MG; 500 MG;
1000 MG FILM-COATED TABLETS
Read all of this leaflet carefully before you start taking
this medicine.
−
Keep this leaflet. You may need to read it again.
−
If you have any questions, ask your doctor or pharmacist.
−
This medicine has been prescribed for you personally
or your child.
Don’t pass it on to other people - it may harm them even
if their symptoms seem to be the same as yours.
−
If any of the side effects gets serious, or if you notice
any side effects not listed in this leaflet, please tell your
doctor or pharmacist.
IN THIS LEAFLET
1.
WHAT KEPPRA IS AND WHAT IT IS USED FOR
2.
BEFORE YOU TAKE KEPPRA
3.
HOW TO TAKE KEPPRA
4.
POSSIBLE SIDE EFFECTS
5.
HOW TO STORE KEPPRA
6. FURTHER INFORMATION
1.
WHAT KEPPRA IS AND WHAT IT IS USED FOR
Keppra contains the active ingredient levetiracetam. It
belongs to antiepileptic medicines, which are used to treat
fits (
seizures
) in epilepsy.
On its own, Keppra is used to treat:
•
partial onset seizure with or without secondary
generalisation (the epilepsy form in which the fits
initially affect only one side of the brain, but could
thereafter extend to larger areas on both sides of the
brain) - in adults and adolescents from 16 years of age
with newly diagnosed epilepsy
As an add-on to other antiepileptic medicines, Keppra is
used to treat:
•
partial onset seizures with or without generalisation in
adults, adolescents, children and infants from one
month of age with epilepsy
•
myoclonic seizures (short, shock-like jerks of a muscle
or group of muscles) in adults and adolescents from
12 years of age with juvenile myoclonic epilepsy
•
primary generalised tonic-clonic seizures (major fits,
including loss of consciousness) in adults an